SEP 17·SEC EDGARLow
Luo Peter purchased $64K of ADAG
Luo Peter (Chief Executive Officer) purchased 20,290 shares of Adagene Inc. (ADAG) at $3.15 on 2026-09-16.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ADAG
Adagene Inc.
Price · $ADAGvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ADAG in the last 7 days.
Insider · 30dAll trades →
- Buys
- $64K 1 txs
- Sells
- — 0 txs
Luo Peter1× · $64K
10b5-1 share of filings0%
Top stories · $ADAGMore →
AUG 18·SEC EDGAR
DO CUONG V purchased $8K of ADAG
DO CUONG V purchased 2,000 shares of Adagene Inc. (ADAG) at $3.75 on 2026-08-14.
AUG 12·finanznachrichten.de
Adagene Inc.: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Adagene (Nasdaq: ADAG) reported six months ended June 30, 2026 results and clinical updates on muzastotug (ADG126). Cash and equivalents were $127.9 million, extending runway into late 2028. Phase 1b/2 data in MSS CRC with pembrolizumab showed ORR 13% to 31% and median PFS 4.8 to 6.7 months, with Phase 2 results expected in 1H 2027.
ADAG sentiment & insider activity
Recent ADAG coverage spans financial news, insider activity and technology.
In the last 30 days, ADAG insiders filed 1 SEC Form 4 transaction — 1 purchase ($64K) and no sales. The most active reporter was Luo Peter, Chief Executive Officer, with 1 filing.
What's driving ADAG
Minor insider purchase; limited price impact.
This is a routine insider buy disclosure with limited incremental signal, since it is a small, non-10b5-1 purchase and provides no new company fundamentals.
The update strengthens the clinical narrative for muzastotug as a CTLA-4 SAFEbody backbone, while extending cash runway into late 2028.
The Form 4 discloses an insider buy, but it is not a fundamental catalyst like guidance, trial results, or a deal.
The appointment of a prominent oncology R&D expert to Adagene's advisory board signals strategic focus on advancing clinical programs, particularly ADG126. This may positively influence investor sentiment and potentially lead to increased stock valuation.
AlphAI scores every news story that mentions ADAG with an AI model for sentiment and relevance, and aggregates insider trades from Adagene Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ADAG
Score
Luo Peter purchased $64K of ADAG
Luo Peter (Chief Executive Officer) purchased 20,290 shares of Adagene Inc. (ADAG) at $3.15 on 2026-09-16.
1 min readDO CUONG V purchased $8K of ADAG
DO CUONG V purchased 2,000 shares of Adagene Inc. (ADAG) at $3.75 on 2026-08-14.
1 min readAdagene Inc.: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Adagene (Nasdaq: ADAG) reported six months ended June 30, 2026 results and clinical updates on muzastotug (ADG126). Cash and equivalents were $127.9 million, extending runway into late 2028. Phase 1b/2 data in MSS CRC with pembrolizumab showed ORR 13% to 31% and median PFS 4.8 to 6.7 months, with Phase 2 results expected in 1H 2027.
6 min readLuo Peter purchased $85K of ADAG
Luo Peter (Chief Executive Officer) purchased 23,245 shares of Adagene Inc. (ADAG) at an average of $3.65 ($3.65–$3.65) across 2 trades over 2026-08-04 to 2026-08-05.
2 min read
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
Adagene Inc. has appointed Peter Lebowitz, MD, Ph.D. to its Scientific and Strategic Advisory Board. Dr. Lebowitz, formerly Global Head of Oncology R&D at Johnson & Johnson, brings extensive experience in drug development and is recognized for his contributions to advancing novel therapies from discovery to commercialization. His expertise will guide the continued clinical development of Adagene's lead program, ADG126, a masked anti-CTLA-4 SAFEbody, particularly in strategies for registration-enabling studies and exploring future combination approaches.
3 min read
Adagene Provides Business Update and 2026 Objectives
Adagene Inc. announced unaudited cash and cash equivalents of $74.5 million as of December 31, 2025, providing a sufficient financial runway into late 2027. The company highlighted key accomplishments from 2025, including progress in its muzastotug clinical trials and strategic collaborations with Sanofi, Third Arc Bio, Exelixis, and ConjugateBio. Adagene also outlined its 2026 objectives, focusing on further clinical data updates for muzastotug in various cancer indications and securing additional partnerships.
3 min read
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
Adagene Inc. (ADAG) announced that the FDA granted Fast Track designation to its lead clinical-stage immuno-oncology candidate, muzastotug (ADG126), in combination with Merck’s Keytruda for treating adult patients with microsatellite-stable metastatic colorectal cancer. This designation aims to facilitate drug development and expedite review for serious diseases with unmet medical needs. ADAG shares surged 13.8% following the announcement, reflecting positive investor sentiment.
3 min readAdagene shares jump after FDA awards fast track status to cancer treatment
Adagene Inc. shares rose significantly after the FDA granted fast track designation to its differentiated anti-CD137 agonist antibody, ADG106, for advanced solid tumors and non-Hodgkin lymphoma. This designation aims to accelerate the development and review of treatments for serious conditions with unmet medical needs. ADG106 is currently in Phase I clinical trials in both the U.S. and China.
4 min readAdagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with ...
3 min read
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 min read